This signalling pathway has been associated with resistance to OXA in prostate cancer cells10 and treatment with a CXCR2 antagonist such as SCH-527123, sensitizes cells to OXA in preclinical colon cancer models58. Here, CXCR2 is linked to prostate carcinoma.